Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial
Centre Hospitalier Universitaire de Lille · Hôpital Claude Huriez · +9 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
2,244
total citations
- FWCI
- 58.27
- Percentile
- 100%
- References
- 33
Citations per year
Authors
11Topics & keywords
Topics
Keywords
- Adalimumab
- Medicine
- Placebo
- Internal medicine
- Crohn's disease
- Adverse effect
- Randomized controlled trial
- Gastroenterology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.